PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.
Erica L MayerYue RenNikhil WagleReshma L MahtaniCynthia X MaAngela M DeMicheleMassimo CristofanilliJane MeiselKathy D MillerYara G AbdouElizabeth C RileyRubina QamarPriyanka SharmaSonya A ReidNatalie SinclairMeredith FaggenCaroline C BlockNaomi Y KoAnn H PartridgeWendy Y ChenMichelle DeMeoVictoria AttayaAmanda OkpoeboJillian AlbertiYuan LiuEric GauthierHarold J BursteinMeredith M ReganSara M TolaneyPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
The addition of palbociclib to fulvestrant did not improve PFS versus fulvestrant alone among patients with hormone receptor-positive/HER2- MBC whose disease had progressed on a previous CDK4/6i plus AI. The increased PFS seen with the addition of avelumab warrants further investigation in this patient population.
Keyphrases
- metastatic breast cancer
- epidermal growth factor receptor
- phase ii study
- tyrosine kinase
- cell cycle
- advanced non small cell lung cancer
- endothelial cells
- open label
- locally advanced
- artificial intelligence
- case report
- induced pluripotent stem cells
- pluripotent stem cells
- machine learning
- cell death
- study protocol
- placebo controlled
- cell cycle arrest